Caplin Point Laboratories: The financial results for the period ended September 30, 2026

What happened

Caplin Point Laboratories (CAPLIPOINT) filed a disclosure with the exchanges on 12 November 2026 at 01:07 PM titled "The financial results for the period ended September 30, 2026".

Company snapshot

Caplin Point Laboratories is a small-cap company in the Healthcare sector, with a market value of about ₹18,863 crore.

The stock last traded at ₹2,481.6, against a 52-week range of ₹1,500.3–₹2,990 (17.0% below the high).

Before this filing the shares had moved +1.7% over the month and −4.8% over three months. Average daily turnover over the last 20 sessions was about ₹19.34 crore.

Promoters held 70.57% at the end of Q1 FY27. Foreign institutions owned 5.75% and domestic institutions 2.49%.

What history shows

This is not the company's first results disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.

Across 300 similar disclosures by other Healthcare companies, shares moved +1.4% on average the next day and +2.6% over five days; 58% of them rose the next day.

Market-wide, 11,631 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 43% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• Management commentary, margins and order book or guidance in the investor presentation.
• 12 November 2026: Board meeting — Financial Results.

In the news

Recent coverage elsewhere (links open the original publisher):

• Caplin Point H1 FY27 Revenue ₹1,307 Cr, PAT ₹361 Cr — InvestyWise, 12 Nov 2026
• Caplin Point PAT grows 13.8% in Q2 FY27 — InvestyWise, 12 Nov 2026

Source

• Exchange filing (PDF)